Q2 2026 Caris Life Sciences Inc Earnings Call Transcript
Key Points
- Record clinical volume in Q2 2026, with 59,200 cases completed, up 18% year-over-year and 12% sequentially, driven by the commercial expansion.
- Total revenue increased 45% year-over-year to $263.7 million, with molecular profiling services revenue up 55% to $252.3 million.
- GAAP gross margin expanded to 68%, up from 63% in the prior year, and the company achieved its fifth consecutive quarter of positive adjusted EBITDA ($55.7 million) and free cash flow ($6.4 million).
- Launched Caris Detect, a multi-cancer early detection test covering 58 cancer types, and received strong interest from channel partners like Everlywell, with demand potentially exceeding supply.
- The company raised its full-year 2026 revenue guidance to $1.03 billion-$1.04 billion (27%-28% growth), driven by strong molecular profiling performance and a record blended ASP of over $3,850.
- Expanded the Precision Oncology Alliance to 101 members, including UC San Francisco and Northwell Health, and grew covered lives for Caris Assure to 131.9 million.
- Advanced the pipeline with the launch of ChromaSeeq (heme therapy selection) and MI Clarity V2 (breast cancer recurrence risk), and is on track to launch an MRD assay in the second half of 2026.
- Pharma R&D Services revenue was lower than expected at $11.4 million, reflecting timing of deliverables and a strategic shift away from smaller one-time deals.
- The company faces potential capacity constraints for Caris Detect, with management acknowledging possible back orders as demand may outpace the rollout and lab capacity expansion.
- GAAP net loss was $0.6 million, which included a $25 million one-time extinguishment charge from refinancing its term loan in April.
- Operating expenses increased by $21 million year-over-year to $152.7 million, driven by investments in commercial expansion and product pipeline, including Caris Detect.
- The company expects a sequential decline in EBITDA in Q3 2026 (projected $10 million-$16 million) due to continued investments, with free cash flow expected to be neutral by the end of Q3.
- Caris Detect is currently self-pay only, with no near-term plans for CMS reimbursement, and the company is still awaiting New York State approval for its liquid biopsy, which could limit market access.
- The MRD assay launch is pending validation and clinical outcome data maturity, which may take at least another 6 months, delaying potential revenue contribution.
Good day, everyone, and welcome to the Caris Life Sciences Q2 2026 Earnings Call. My name is Tanya, and I'll be your conference operator today. (Operator Instructions) After the prepared remarks, there will be a question-and-answer session. As a reminder, this call is being recorded.
I would now like to hand the call over to Russ Denton at Caris. Please go ahead.
Thank you. Earlier today, Caris Life Sciences released financial results for the quarter ended June 30, 2026. Joining from Caris today are David Dean Huber, our Founder, Chairman and CEO; and David Spetsler, our President; Brian Briley, our Vice Chairman and EVP; and Luke Power, our CFO.
Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to materially differ from those anticipated.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
